Immunovant Ownership | Who Owns Immunovant?


OverviewForecastRevenueFinancialsChart

Immunovant Ownership Summary


Immunovant is owned by 53.69% institutional investors, 55.64% insiders. Fmr is the largest institutional shareholder, holding 7.59% of IMVT shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.15% of its assets in Immunovant shares.

IMVT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockImmunovant53.69%55.64%-9.34%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr10.48M7.59%$276.77M
Vanguard group6.51M4.71%$171.86M
Blackrock4.92M3.56%$129.79M
Armistice capital3.40M2.46%$89.68M
Deep track capital, lp2.88M2.09%$76.13M
State street2.72M1.97%$71.78M
Viking global investors lp2.32M1.68%$61.27M
Alpine global management1.91M1.38%$50.36M
Woodline partners lp1.82M1.32%$48.14M
T. rowe price investment management1.63M1.18%$42.91M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Alpine global management1.91M8.76%$50.36M
Tyro capital management250.62K3.00%$6.62M
Two seas capital lp692.41K2.97%$18.28M
Prosight management, lp325.00K2.56%$8.58M
Adar1 capital management476.54K2.38%$12.58M
Deep track capital, lp2.88M2.27%$76.13M
Paradigm biocapital advisors lp1.36M1.38%$35.98M
Logos global management lp575.00K1.22%$15.18M
Redmile group720.18K1.15%$19.01M
Boxer capital825.00K1.15%$21.78M

Top Buyers

HolderShares% AssetsChange
Fmr10.48M0.02%2.83M
Deep track capital, lp2.88M2.27%2.39M
T. rowe price investment management1.63M0.03%1.63M
Armistice capital3.40M1.13%1.23M
Norges bank601.86K0.00%601.86K

Top Sellers

HolderShares% AssetsChange
Point72 asset management---1.38M
Logos global management lp575.00K1.22%-1.20M
State street2.72M0.00%-922.95K
Commodore capital lp---750.99K
First turn management---695.43K

New Positions

HolderShares% AssetsChangeValue
T. rowe price investment management1.63M0.03%1.63M$42.91M
Norges bank601.86K0.00%601.86K$15.89M
Canada pension plan investment board199.80K0.01%199.80K$5.27M
Alps advisors113.93K0.02%113.93K$3.01M
Mirae asset global etfs32.96K0.00%32.96K$867.92K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-11.00
Cibc private wealth group-17.00
Innealta capital-59.00
Principal securities-70.00
Barclays-100.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2024204-4.23%78,645,3575.27%532.05%94-14.55%64-
Jun 30, 2024211-10.21%74,707,0257.20%542.33%1090.93%63-23.17%
Mar 31, 2024235-7.11%69,688,1951.94%482.16%108-20.00%823.80%
Dec 31, 202325318.22%68,360,1722.16%471.80%1351.50%7971.74%
Sep 30, 202321436.31%66,916,90020.66%512.53%13349.44%464.55%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S4.62M3.15%164.70K
Fidelity Growth Compy Commingled Pl O4.45M3.04%196.00K
Fidelity Growth Company Fund3.38M2.31%98.83K
Vanguard Total Stock Mkt Idx Inv2.10M1.43%-14.65K
SPDR® S&P Biotech ETF1.68M1.15%18.58K
Vanguard Small Cap Index1.65M1.13%3.25K
iShares Russell 2000 ETF1.50M1.02%-3.37K
T. Rowe Price US Small-Cap Core Equity1.29M0.88%1.29M
T. Rowe Price Small-Cap Stock1.29M0.88%1.29M
Fidelity Growth Company K61.13M0.77%16.37K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 02, 2024Pande Atul-Sell$221.19K
Dec 02, 2024Hughes Douglas J.-Sell$154.83K
Nov 20, 2024Levine Mark S. Chief Legal OfficerSell$92.89K
Nov 20, 2024Macias William L. Chief Medical OfficerSell$85.33K
Nov 20, 2024Barnett Eva Renee Chief Financial OfficerSell$106.23K

Insider Transactions Trends


DateBuySell
2024 Q4-16
2024 Q3-28
2024 Q2-23
2024 Q1-14
2023 Q4126

IMVT Ownership FAQ


Who Owns Immunovant?

Immunovant shareholders are primarily institutional investors at 53.69%, followed by 55.64% insiders and -9.33% retail investors. The average institutional ownership in Immunovant's industry, Biotech Stocks , is 47.04%, which Immunovant exceeds.

Who owns the most shares of Immunovant?

Immunovant’s largest shareholders are Fmr (10.48M shares, 7.59%), Vanguard group (6.51M shares, 4.71%), and Blackrock (4.92M shares, 3.56%). Together, they hold 15.87% of Immunovant’s total shares outstanding.

Does Blackrock own Immunovant?

Yes, BlackRock owns 3.56% of Immunovant, totaling 4.92M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 129.79M$. In the last quarter, BlackRock increased its holdings by 439.33K shares, a 9.81% change.

Who is Immunovant’s biggest shareholder by percentage of total assets invested?

Alpine global management is Immunovant’s biggest shareholder by percentage of total assets invested, with 8.76% of its assets in 1.91M Immunovant shares, valued at 50.36M$.

Who is the top mutual fund holder of Immunovant shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Immunovant shares, with 3.15% of its total shares outstanding invested in 4.62M Immunovant shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools